The Complete Guide to Clinical Mole Surveillance for Early Melanoma Detection in the UK

What Surveillance Adds That a One-Off Check Cannot

A consultant examining a lesion for the first time is answering the question does this look dangerous? That question has limits. Many early melanomas look unremarkable in isolation, and many entirely benign lesions look alarming. Judgement in that situation relies on pattern recognition, and it is right far more often than not — but it is working with one frame of a film.

Surveillance answers a different question: has this changed? That question is easier to answer accurately, and it is the question that matters. A lesion photographed at high resolution and re-photographed twelve months later can be compared directly, and the comparison is objective rather than remembered.

Both have their place. If one lesion is worrying you and the rest of your skin is unremarkable, a single assessment is the proportionate answer. Surveillance earns its value where there is a lot to keep track of.

How a Mole Map Is Carried Out

The process at this clinic runs in five stages, and understanding them makes the appointment considerably less abstract.

1. Consultation. A consultant plastic surgeon reviews your medical history and skin cancer risk factors, discusses anything you have noticed yourself, examines the skin, and identifies areas needing particular attention.
2. FotoFinder® imaging. Full-body photography from standardised angles, then dermoscopic images of individual lesions and high-resolution capture of anything of concern. Standardisation is what makes the images comparable next year.
3. AI analysis. Algorithms compare the current images against previous scans where they exist, flag new or evolving lesions automatically, and highlight areas for clinical attention.
4. Expert review. The consultant reviews the findings and the AI output, assesses flagged areas clinically, and makes a recommendation — removal, biopsy or continued monitoring. Anything urgent is discussed immediately rather than held for a report.
5. Personalised report. A written record of the findings, recommended next steps, sun protection advice matched to your risk profile, and the timing of the next screening.

Each stage is covered in more depth in what happens at a mole mapping appointment, and the document you receive at the end is explained in understanding your mole map report.

What the AI Does — and What It Does Not

This deserves stating plainly, because the marketing around AI in dermatology has run some distance ahead of the reality.

The software compares images and flags differences. It is good at exactly that: detecting a change of a few pixels in size, shape or colour distribution between two standardised photographs taken a year apart — a difference no human reliably perceives from memory. Where it is used to compare, rather than to diagnose, it is doing something people genuinely cannot do.

What it does not do is decide. The final assessment is always made by a consultant plastic surgeon, who reviews the flagged lesions clinically and determines what happens next. The AI produces a shortlist; it does not produce a diagnosis, and a flag is not a finding.

The distinction matters when comparing this with a consumer phone app. An app photographs a lesion in uncontrolled lighting, without dermoscopy, with no baseline and no clinician, and returns a risk score. The technology in the two situations shares a name and very little else. More on that in how the FotoFinder system works and digital dermoscopy explained.

Who Benefits, and Who Does Not Need It

Surveillance is worth most where there is either a lot to track or a raised background risk. The recognised indications are:

• Many moles — more than about 50 in total, or moles that are unusually shaped or coloured. See whether having many moles raises risk.
• Fair or freckled skin that burns easily and rarely tans — Fitzpatrick types and risk.
• Family history of melanoma or skin cancer in a close relative.
• Personal history of skin cancer or precancerous lesions.
• Significant sun exposure — regular UV, repeated sunburn, or tanning bed use.
• Immunosuppression, including after organ transplant.
• Recent change you have noticed in a mole’s size, colour or shape, or bleeding.

Equally worth saying: if you have a handful of stable moles, no family history, no significant sun damage and nothing that has changed, annual photographic surveillance is not something you need. A baseline still has value for future comparison, and plenty of people choose it for that reason alone — but it should be presented as a choice rather than a requirement. The full picture is in who is at high risk of melanoma, and the choice between assessing one lesion and mapping the whole skin is compared in spot check or full-body mapping.

How Often, by Risk Group

Twelve months is the default, but the interval is set by risk rather than by protocol. The schedule used here:

The interval exists because comparison is more reliable at a consistent spacing: the eye and the software are both looking for change against a known elapsed time. More in how often mole mapping should be repeated and on why the first map matters disproportionately in why your baseline matters most.

What Surveillance Actually Produces Here

Most pages about mole mapping describe the technology. Fewer describe what comes out of it. These are the clinic’s own figures, from roughly 70 to 90 full mole maps a year.

Two of those rows deserve attention because they run in opposite directions. Between three and six times a year, a lesion nobody would have removed on appearance alone is removed because the comparison showed it had changed. And five to ten times a year, a lesion that would have been excised on first inspection is left alone, because the images showed it had not moved — which on a face or a shoulder means a scar that did not need to happen.

The remaining figures are worth reading honestly too. If 15% of excised lesions are malignant, then 85% are not. Surveillance produces removals that turn out to be unnecessary in hindsight, and that cost is real.

“Most of what we find will be nothing, and the point of the map is not to find something today. Patients arrive expecting a verdict. What they are actually buying is a reference point — and the value of it arrives a year from now.”— Mr Onur Gilleard, Consultant Plastic Surgeon

If Something Is Found

A flagged lesion is not a diagnosis, and most flagged lesions turn out to be benign. Where clinical assessment agrees that a lesion needs dealing with, the pathway is straightforward.

The lesion is removed and sent for histological examination. For a pigmented lesion that might be a melanoma this means excision of the whole lesion rather than sampling part of it, because the depth of the lesion — not just its presence — determines what happens next, and depth cannot be assessed from a fragment. Techniques that destroy tissue in place are not appropriate here for the same reason: they leave nothing to examine.

Histological analysis is charged at £180 and is applied where the lesion’s features warrant it rather than routinely. The steps are set out in what happens when a suspicious mole is found and urgent assessment and removal.

The Honest Limits

Surveillance is a strong tool and it is not a complete one. Four limitations are worth knowing before booking.

It photographs skin, not everything

Standardised imaging covers visible skin surfaces in a set of poses. Outside that: the scalp beneath hair, which is parted and examined directly; nail beds, where subungual melanoma presents as a longitudinal pigmented band rather than as a mole and needs specific assessment; palms, soles, finger webs and between the toes, where acral melanoma occurs; skin folds — inframammary, axillary, behind the ears; genital and perianal skin, examined only on consent and indication; and mucosal sites, which are outside scope entirely. Worth adding because patients assume otherwise: uveal melanoma is a matter for optometry and ophthalmology, not for skin surveillance.

It detects change, so the first map detects less

At baseline there is nothing to compare against, which is why the first map is best understood as an investment in the second. A lesion that is already abnormal will of course be identified at the first visit; a lesion that is becoming abnormal will not be, until there is a previous image to set it against.

Nodular melanoma moves faster than the interval

Most melanomas grow slowly enough for annual comparison to catch them. Nodular melanoma can arise and progress within months, often on skin that had no mole before. Annual imaging does not replace noticing something new between appointments — see melanoma on clear skin.

Two cancers it does not reliably find

Total-body photography is built around pigmented lesions. It has real difficulty with amelanotic melanoma, which carries little or no pigment and appears pink or skin-coloured rather than mole-like, and it does not reliably detect basal cell or squamous cell carcinoma — which are, between them, considerably more common than melanoma. Those are found by examination, not by comparison, which is why a map does not replace a full skin check — see annual skin cancer screening.

Detection is not the same as prevention — and not the same as survival

Surveillance with total-body photography and sequential dermoscopy in high-risk patients is associated with melanoma being detected at lower Breslow thickness, and Breslow thickness is the strongest predictor of survival. That is the honest claim. There is no randomised trial showing that mole mapping reduces melanoma mortality — such a trial would be very large and has not been done. Anyone telling you otherwise is going beyond the evidence.

It can create anxiety as well as resolve it

Surveillance finds dysplastic naevi of uncertain significance that would never have caused harm, and each one carries a decision, a scar and a period of worry. Some patients leave a mole map more anxious than they arrived. That is managed with pre-agreed thresholds for excision rather than reacting to every atypical feature, and by using short-term sequential imaging instead of reflex removal where a lesion is equivocal but not alarming.

What It Costs

Mole mapping is not routinely funded on the NHS as a screening service; the NHS route is for lesions that are already suspicious, through a GP, on the urgent suspected-cancer pathway. That distinction — screening versus diagnosis — is also how private medical insurers usually draw their line, and it explains why a policy may decline a mole map but cover the removal of something found by one. The criteria are set out in removal on the NHS.

To arrange an appointment, see mole mapping at 101 Harley Street or contact the clinic.

What People Ask on Reddit About Mole Mapping — A Surgeon’s Honest Take

“Is mole mapping actually worth it, or is it just an expensive photo session?”

It is worth it in proportion to how much there is to track. For someone with 80 moles, fair skin and a burnt childhood, comparison imaging does something no examination can. For someone with six stable moles, it is an expensive photo session, and that should be said out loud rather than discovered later.

“My GP said my moles are fine. Why would I pay for this?”

If a GP has examined a specific lesion and is not concerned, that is usually the end of it. What a GP appointment does not produce is a record. The value of surveillance is not a second opinion on today’s appearance; it is a baseline for next year’s comparison.

“Does the AI actually find things, or is it a gimmick?”

It finds differences between two images taken a year apart, reliably and at a scale below what anyone perceives from memory. It does not diagnose, and a flagged lesion is not a finding — a consultant assesses every one. Used as a comparison tool it earns its place; sold as a diagnosis it would not.

“I’ve got loads of moles and I’m anxious about all of them. Will this make it better or worse?”

Usually better, for a specific reason: most anxiety about moles is anxiety about uncertainty, and a documented baseline converts “I think this one is different” into something answerable. It does not suit everyone, and if surveillance is generating more distress than it resolves, that is a reason to discuss the interval rather than to continue silently.

Frequently Asked Questions

What is clinical mole surveillance?

The practice of recording the skin photographically and dermoscopically so that lesions can be compared over time rather than judged on a single appearance. It answers the question “has this changed?” instead of “does this look dangerous?”, which is both easier to answer accurately and more informative.

How much does mole mapping cost?

The complete mole mapping package is £300. Where a lesion is subsequently removed, mole removal is £350 with additional moles at £200, and histological analysis where warranted is £180.

How often should it be repeated?

Every 12 months as standard. The interval is long enough for meaningful change and short enough that a changing lesion is still early. Shorter intervals are used for higher-risk situations such as a previous melanoma or atypical mole syndrome under monitoring.

Is mole mapping available on the NHS?

Not as a screening service. The NHS pathway is for lesions that are already suspicious and runs through a GP referral, with urgent cases going onto the two-week suspected-cancer route. Screening for the purpose of establishing a baseline is a private service.

Does AI decide whether a mole is dangerous?

No. The software compares images and flags differences for attention; the clinical assessment and the decision are made by a consultant plastic surgeon. A flag is a prompt to look, not a finding.

Who should have mole mapping?

People with more than about 50 moles or atypical moles, fair skin that burns easily, a family or personal history of skin cancer, significant sun exposure or tanning bed use, or immunosuppression. Anyone who has noticed a change should be assessed regardless of category.

Can mole mapping miss a melanoma?

It can. Sites that are hard to image, such as the scalp under hair, nail beds and mucosal surfaces, need direct examination. Nodular melanoma can also develop and progress between annual appointments, which is why noticing something new yourself still matters.

Is the first map less useful than later ones?

In one specific sense, yes: at baseline there is nothing to compare against, so the surveillance function has not started. Anything already abnormal is identified at the first visit, but the comparison that catches a lesion in the act of changing only becomes possible at the second.